Legend Biotech Corp. (LEGN) PT Raised to $86 at RBC Capital

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Legend Biotech Corp. (LEGN) PT Raised to $86 at RBC Capital

Legend Biotech Reports First Quarter 2024 Results and Recent Highlights

May 13, 2024 7:00 AM EDT

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $157 million EC and US FDA approved CARVYKTI® label expansion in earlier lines of treatment for adult patients with relapsed and lenalidomide-refractory multiple myeloma Legend and Johnson & Johnson enter into Master Manufacturing and Supply Services Agreement with Novartis Pharmaceuticals Corporation On April 5, Legend Biotech earned a milestone payment of $45 million in connection with FDAs approval of CARVYKTIs label expansion to treat 2L+ MM, in accordance with the Janssen Agreement* Cash and cash equivalents, deposits, and short-term investments of $1.3... More